Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of hypertonic albumin replacement fluid in plasma exchange therapy (Alb-PE-01)
jRCTs071250083Recruiting
- Sponsor
- KM Biologics
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of albumin (human) in myasthenia gravis (MG), systemic lupus erythematosus (SLE) and chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by KM Biologics. Primary endpoint: Incidence rate of adverse events and side effects during plasma exchange treatment. Started Apr 2026; status: recruiting.
02
Drugs
albumin (human)
03
Conditions
myasthenia gravis (MG)systemic lupus erythematosus (SLE)chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCTs071250083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250083.